In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of P3 Health Partners Inc (NASDAQ: PIII) closed at $0.22 in the last session, down -8.46% from day before closing price of $0.24. In other words, the price has decreased by -$8.46 from its previous closing price. On the day, 0.31 million shares were traded. PIII stock price reached its highest trading level at $0.258 during the session, while it also had its lowest trading level at $0.221.
Ratios:
We take a closer look at PIII’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.53 and its Current Ratio is at 0.53. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.20.
On September 01, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 12 ’24 when Chicago Pacific Founders UGP I bought 80,000 shares for $0.52 per share. The transaction valued at 41,600 led to the insider holds 77,105,438 shares of the business.
Chicago Pacific Founders UGP I bought 80,000 shares of PIII for $39,952 on Sep 13 ’24. The 10% Owner now owns 77,185,438 shares after completing the transaction at $0.50 per share. On Sep 11 ’24, another insider, Chicago Pacific Founders UGP I, who serves as the 10% Owner of the company, bought 80,000 shares for $0.56 each. As a result, the insider paid 44,728 and bolstered with 77,025,438 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PIII now has a Market Capitalization of 123185504 and an Enterprise Value of 311472352. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.05 while its Price-to-Book (P/B) ratio in mrq is 0.30. Its current Enterprise Value per Revenue stands at 0.222 whereas that against EBITDA is -3.594.
Stock Price History:
The Beta on a monthly basis for PIII is 0.98, which has changed by -0.83053434 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, PIII has reached a high of $1.44, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is -13.41%, while the 200-Day Moving Average is calculated to be -53.46%.
Shares Statistics:
According to the various share statistics, PIII traded on average about 664.28K shares per day over the past 3-months and 596070 shares per day over the past 10 days. A total of 161.97M shares are outstanding, with a floating share count of 91.41M. Insiders hold about 43.87% of the company’s shares, while institutions hold 20.58% stake in the company. Shares short for PIII as of 1730332800 were 957117 with a Short Ratio of 1.09, compared to 1727654400 on 1082190. Therefore, it implies a Short% of Shares Outstanding of 957117 and a Short% of Float of 0.69999998.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $378.88M. It ranges from a high estimate of $389.54M to a low estimate of $365.4M. As of the current estimate, P3 Health Partners Inc’s year-ago sales were $346.86MFor the next quarter, 4 analysts are estimating revenue of $407.15M. There is a high estimate of $434.8M for the next quarter, whereas the lowest estimate is $379.5M.
A total of 4 analysts have provided revenue estimates for PIII’s current fiscal year. The highest revenue estimate was $1.52B, while the lowest revenue estimate was $1.5B, resulting in an average revenue estimate of $1.51B. In the same quarter a year ago, actual revenue was $1.27BBased on 4 analysts’ estimates, the company’s revenue will be $1.52B in the next fiscal year. The high estimate is $1.7B and the low estimate is $1.37B.
